(Reuters) – U.S.-based Carlyle Group Inc has agreed to buy a 20% stake in India’s Piramal Enterprises Ltd’s pharmaceutical businesses for about $490 million, the companies said in a statement on Saturday.
The capital increase aims to accelerate Piramal Pharma’s organic and inorganic growth plans, according to the statement.
(Reporting by Maria Ponnezhath in Bengaluru; Editing by William Mallard)
